secwatch.observer — SEC 8-K summary
======================================

Issuer:     HARVARD BIOSCIENCE INC (HBIO)
CIK:        0001123494
Form:       8-K
Filed at:   2024-08-08T23:59:59+00:00
Accession:  0001171843-24-004562
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Harvard Bioscience Q2 revenue $23.1M (-20% YoY); GAAP net loss $2.9M
--------------------------------------------------------------------

- Q2 revenue $23.1M, down 20% from $28.8M; gross margin 57.2% vs 58.0%.
- GAAP operating loss $2.1M vs income $0.8M; diluted GAAP EPS -$0.07 vs -$0.02.
- Adjusted EBITDA $1.3M (5.5% margin) vs $3.9M (13.6%); adjusted EPS $0.00.
- Q2 cash from operations $0.6M vs $5.4M; cost actions expected to save $4M annually.
- CEO cites challenging market with recovery delayed to later in second half.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1123494/000117184324004562/0001171843-24-004562-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1123494/000117184324004562/f8k_080824.htm
  HTML page:      https://secwatch.observer/filing/0001171843-24-004562

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer